Peel Hunt restated their buy rating on shares of Hikma Pharmaceuticals Plc (LON:HIK) in a research note released on Wednesday morning. They currently have a GBX 2,340 ($28.90) price objective on the stock.

HIK has been the subject of several other research reports. JPMorgan Chase & Co. reaffirmed an overweight rating on shares of Hikma Pharmaceuticals Plc in a report on Thursday, November 17th. Numis Securities Ltd downgraded shares of Hikma Pharmaceuticals Plc to an add rating and set a GBX 2,350 ($29.02) price objective for the company. in a report on Friday, March 10th. Jefferies Group LLC upped their price objective on shares of Hikma Pharmaceuticals Plc from GBX 2,065 ($25.50) to GBX 2,162 ($26.70) and gave the stock a buy rating in a report on Tuesday, January 17th. Citigroup Inc reaffirmed a neutral rating on shares of Hikma Pharmaceuticals Plc in a report on Wednesday, November 16th. Finally, AlphaValue reaffirmed a buy rating and issued a GBX 2,431 ($30.02) price objective on shares of Hikma Pharmaceuticals Plc in a report on Wednesday, November 30th. One research analyst has rated the stock with a sell rating, three have given a hold rating and six have assigned a buy rating to the company’s stock. Hikma Pharmaceuticals Plc presently has an average rating of Buy and an average price target of GBX 2,353.67 ($29.07).

Shares of Hikma Pharmaceuticals Plc (LON:HIK) opened at 2129.28 on Wednesday. The stock’s market capitalization is GBX 4.81 billion. Hikma Pharmaceuticals Plc has a one year low of GBX 1,575.00 and a one year high of GBX 2,703.00. The stock’s 50 day moving average is GBX 2,047.69 and its 200-day moving average is GBX 1,925.38.

Your IP Address:

The firm also recently declared a dividend, which will be paid on Thursday, May 25th. Shareholders of record on Thursday, April 6th will be issued a GBX 0.22 ($0.00) dividend. This represents a yield of 0.78%. This is an increase from Hikma Pharmaceuticals Plc’s previous dividend of $0.21. The ex-dividend date is Thursday, April 6th.

About Hikma Pharmaceuticals Plc

Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company develops, manufactures and markets a range of branded and non-branded generic pharmaceutical products in solid, semi-solid, liquid and injectable final dosage forms, across the United States, the Middle East and North Africa (MENA) region and Europe.

Receive News & Ratings for Hikma Pharmaceuticals Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals Plc and related companies with MarketBeat.com's FREE daily email newsletter.